DiaSorin SpA
MIL:DIA
Gross Margin
DiaSorin SpA
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IT |
|
DiaSorin SpA
MIL:DIA
|
5.1B EUR |
66%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
219.7B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
175.8B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
138B USD |
68%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
133.6B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD |
66%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.5B USD |
45%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
49.4B EUR |
38%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
40.8B USD |
79%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
261.4B CNY |
64%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
31.9B USD |
61%
|
DiaSorin SpA
Glance View
In the heart of the global healthcare landscape, DiaSorin SpA stands as a testament to innovation and precision in the field of biotechnology. Founded in 1968 in Italy, the company built its reputation on developing and producing diagnostic tests that help identify and monitor diseases. With a primary focus on immunodiagnostic and molecular diagnostic products, DiaSorin excels in creating high-quality, reliable solutions that clinicians and labs around the world depend on. Their product portfolio ranges widely, covering infectious diseases, oncology, endocrinology, and more. By leveraging cutting-edge research and development processes, DiaSorin not only prioritizes accuracy and efficiency in its testing solutions but also adapts to the ever-evolving demands of the medical world, cementing its role as a leader in diagnostic innovation. From a business perspective, DiaSorin's revenue streams are deeply intertwined with its prowess in developing proprietary testing technologies, including both instruments and consumables. The company operates with a dual-channel business model where it sells diagnostic machines to laboratories, hospitals, and clinics while simultaneously providing the reagents and kits necessary for these machines' continuous operation. This approach ensures not only a sale of sophisticated equipment but also a recurring revenue stream from the consumables needed for diagnostics. With a strategic emphasis on research and partnerships, DiaSorin has expanded its reach globally, ensuring its products meet diverse regional healthcare requirements. Through a combination of robust product offerings and strategic global expansion, DiaSorin continues to thrive and maintain its position as a pivotal contributor to the field of diagnostic medicine.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on DiaSorin SpA's most recent financial statements, the company has Gross Margin of 65.9%.
You don't have any saved screeners yet